Avastin approved in EU for rcc

Avastin (bevacizumab) has been approved in Europe for first-line treatment of renal cell carcinoma.

As of November 2007, Avastin has not been approved for rcc in either the U.S. or Canada. Avastin is approved in Canada for colorectal cancer, but is not funded in every province.


Roche has announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Avastin (bevacizumab) for the first-line treatment of patients with the most common form of advanced kidney cancer, renal cell carcinoma (RCC). The CHMP’s decision is based on data from the pivotal phase III AVOREN trial, which showed that adding Avastin to interferon gave patients with advanced RCC the chance to live twice as long without their disease progressing (“progression free survival”) compared with interferon (IFN) alone.

Full details at:


Kidney Cancer Canada